myhep-dvir tablets price in india

myhep-dvir

•  myhep dvir tablet is a effective combination of two esteemed anti-viral compounds   like Sofosbuvir & Daclatasvir. 
•  Sofosbuvir is a present as prodrug and exhibits its action by converting into active   moiety. 
•  Daclatasvir is not used as single, must be use in combination of other anti-viral agent   called sofosbuvir and expels prominent effect against hepatitis virus

                                                              myhep dvir

MECHANISM OF ACTION

• MYHEP DVIR notwithstanding tablet has two fragments Sofosbuvir and Daclatasvir 
• Daclatasvir performs Non essential 5A protein is the key for viral duplication. Daclatasvir interfere with the activity of NS5A protein, this may prompts viral destruction. 
• Sofosbuvir is a prohibitor of nucleotide basic, especially blocks HCV non-helper protein 5B RNA subordinate RNA polymerase. 
• Sofosbuvir encounter intracellular absorption, which convey pharmacologically powerful compound like uridine basic triphosphate 
• Sofosbuvir intercede into RNA of hepatitis C contamination with the help of NS5B polymerase. This may goes about as chain eliminator.

 FOOD DRUG INTERACTION

• Food drug interaction is not possible during the therapy. 
• Maintained in diet after getting advice from the physician 
• Concomitant use of ribavirin, should not be taken on an empty stomach.

 SAFETY MEASURES

• This adverse condition may reduced by; 
• Examine the patients who are going to receive the MYHEP DVIR tablet formerly with HBV infection present or not. The patients who are not taking anti-hepatitis B viral drugs may occur. 
• To avoid this condition, patients must be investigating by undergone liver function test.

Metabolism

• Metabolism of sofosbuvir is involved in liver, with the help of carboxyl esterase 1 or cathepsin A 
• Nearly 99% of Daclatasvir is binding to protein and it is substrate of CYP3A.

MYHEP DVIR dosing regimen;

• The usual dose of MYHEP DVIR tablet is one tablet should be taken as a single dose by administering with food or without food. 
• On severe condition, MYHEP DVIR must be combine with ribavirin. Patients suffering in HCV genotype I or III with decompensated cirrhosis or post transplantation; the initial dose of ribavirin is 600mg as a single dose, elevating dose up to 1000mg. In compensated cirrhosis; the starting dose of ribavirin should be calculated on the basis of body weight of the suspected patients. In patient with weight of at least 75kg: 1200mg of ribavirin should be considered.